HCV antibody response and genotype distribution in different areas and races of China

International Journal of Biological Sciences

Volumn 5, Issue 5, 2009, Pages 421-427

  Jia, Leili ^a   Yu, Jiyun ^b   Song, Hongbin ^a   Yang, Jinliang ^c   Liu, Xuelin ^a   Wang, Yong ^a   Xu, Yuanyong ^a   Zhang, Chuanfu ^a   Zhong, Yanwei ^d   Li, Qiao ^a,b,e  

^a The Institute for Disease Prevention and Control of PLA   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c SICHUAN UNIVERSITY   (China)

^d BEIJING 302 HOSPITAL   (China)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anti hcv; Elisa; Genotype; Hepatitis c virus; Neutralization test

Indexed keywords

HEPATITIS C VIRUS;

HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; ASIAN; BLOOD; CHILD; CHINA; COMPARATIVE STUDY; DNA SEQUENCE; ETHNOLOGY; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; VIROLOGY;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHINA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 70249086307     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.421     Document Type: Article

References (32)

1. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov. 2007;6(12):991-1000.
2. Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. Expert Rev Vaccines. 2008;7(7):915-23.
3. Missale G, Cariani E, Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Dig Liver Dis. 2004;36(11):703-11.
4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology. 2004;39(1):5-19.
5. Halfon P, Neumann AU, Bourliere M, et al. Slow viral dynamics of hepatitis C virus genotype 4. J Viral Hepat. 2003;10(5):351-3.
6. Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004;85(Pt 11):3173-88.
7. Eiras A, Franco E, Montoro JA, Planelles D, Villaescusa R. HCV NAT (minipool RT-PCR) and HCV core antigen ELISA. Trans- fusion. 2003;43(1):118.
8. Rodriguez M, Riezu-Boj JL, Ruiz M, et al. Immunogenicity of variable regions of hepatitis C virus proteins: selection and modi?cation of peptide epitopes to assess hepatitis C virus genotypes by ELISA. Journal of General Virology. 1999;80:727-38.
9. Hermida M, Ferreiro MC, Barral S, Laredo R, Castro A, Diz DP. Detection of HCV RNA in saliva of patients with hepatitis C virus infection by using a highly sensitive test. J Virol Methods. 2002;101(1-2):29-35.
10. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci U S A. 1992;89(1):187-91.
11. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35(1):201-7.
12. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992;73 (Pt 3):673-9.
13. Song P, Duc DD, Hien B, et al. Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. Clin Diagn Lab Immunol. 1994;1(4):413-8.
14. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol. 1993;74 (Pt 11):2385-90.
15. Fried MW. Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev Gastroenterol Disord. 2004;4(Suppl 1):S8-S13.
16. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946-52.
17. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004;58:391-424.
18. Owsianka AM, Tarr AW, Keck ZY, et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 gly- coprotein. J Gen Virol. 2008;89(Pt 3):653-9.
19. Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis. 1987;156(1):56-63.
20. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ. Efficacy of pro- phylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis. Lancet. 1976;1(7959):557-61.
21. Lavillette D, Morice Y, Germanidis G, et al. Human serum fa- cilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79(10):6023-34.
22. Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of vi- rus-neutralizing antibodies and viral clearance in a sin- gle-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007;104(14):6025-30.
23. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neu- tralization. Proc Natl Acad Sci U S A. 1994;91(16):7792-6.
24. Ishii K, Rosa D, Watanabe Y, et al. High titers of antibodies in- hibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology. 1998;28(4):1117-20.
25. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cyto- fluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A. 1996;93(5):1759-63.
26. Meyer K, Ait-Goughoulte M, Keck ZY, Foung S, Ray R. Anti- body-dependent enhancement of hepatitis C virus infection. J Virol. 2008;82(5):2140-9.
27. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) in- fection. Int J Med Sci. 2006;3:41-46.
28. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000;182(3):698-707.
29. Fretz C, Jeannel D, Stuyver L, et al. HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol. 1995;47(4):435-7.
30. Simmonds P. The origin and evolution of hepatitis viruses in humans. J Gen Virol. 2001;82(Pt 4):693-712.
31. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36(5 Suppl 1):S21-9.
32. Sentandreu V, Jimenez-Hernandez N, Torres-Puente M, et al. Evidence of recombination in intrapatient populations of hepa- titis C virus. PLoS ONE. 2008;3(9):e3239.